[ CAS No. 61837-46-5 ] {[proInfo.proName]}

Name: 61837-46-5|Methyl 2-bromo-4-methylpentanoate|98%
Brand: Ambeed
SKU: A515585
Rating: 96 (25 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 61837-46-5 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 61837-46-5 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 61837-46-5 ]

SDS Specification

Alternatived Products of [ 61837-46-5 ]

Product Details of [ 61837-46-5 ]

CAS No. :	61837-46-5	MDL No. :	MFCD00043896
Formula :	C₇H₁₃BrO₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	SRPGFJDOALJGMR-UHFFFAOYSA-N
M.W :	209.08	Pubchem ID :	12957039
Synonyms :

Safety of [ 61837-46-5 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P305+P351+P338	UN#:	N/A
Hazard Statements:	H227-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 61837-46-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 61837-46-5 ]
Downstream synthetic route of [ 61837-46-5 ]

[ 61837-46-5 ] Synthesis Path-Upstream 1~10

1
[ 67-56-1 ]
[ 646-07-1 ]
[ 61837-46-5 ]

Yield	Reaction Conditions	Operation in experiment
66%	Stage #1: With thionyl chloride In tetrachloromethane at 25 - 65℃; for 0.5 h; Stage #2: With N-Bromosuccinimide; hydrogen bromide In tetrachloromethane; water at 85℃; Stage #3: at 0℃;	Preparation of 2-bromo-4-methyl-pentanoic acid methyl ester: A solution of 4-methyl-pentanoic acid (50 g, 0.43 mol) in carbon tetrachloride (200 mL) at 25° C. was treated with thionyl chloride (125 mL, 1.72 mol). The reaction was then heated to 65° C. and stirred for 30 min. After this time, the reaction was removed from the heat and was then treated with N-bromosuccinimide (100 g, 0.56 mol), carbon tetrachloride (200 mL) and a 48percent aqueous hydrogen bromide (40 drops). The reaction was then heated to 85° C. and stirred overnight. After this time, the reaction was cooled to 0° C. and carefully quenched with methanol (150 mL) until no further gas evolution was observed. The mixture was then filtered and washed with hexanes. The dark solution was concentrated in vacuo. The remaining liquid was then partitioned between water (300 mL) and hexanes (3.x.300 mL). The combined organics were washed with a saturated aqueous sodium bicarbonate solution, dried over anhydrous sodium sulfate, filtered, rinsed and concentrated in vacuo. The obtained residue was distilled in vacuo to afford 2-bromo-4-methyl-pentanoic acid methyl ester as colorless oil (60 g, 66percent); ¹H NMR (300 MHz, CDCl₃): δ 4.28 (t, 1H, J=7.5 Hz), 3.77 (s, 3H), 1.90 (t, 2H, J=7.5 Hz), 1.78-1.71 (m, 1H), 0.93 (dd, 6H, J₁=14.1 Hz, J₂=6.6 Hz). GC-MS: 209 [M]⁺, t_R=5.50 min.

Reference： [1] European Journal of Organic Chemistry, 2011, # 7, p. 1300 - 1309
[2] Patent: US2011/21570, 2011, A1, . Location in patent: Page/Page column 15
[3] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1986, p. 1939 - 1946
[4] Tetrahedron, 1992, vol. 48, # 23, p. 4773 - 4792
[5] Chemistry - A European Journal, 2016, vol. 22, # 51, p. 18368 - 18372

2
[ 328-39-2 ]
[ 18107-18-1 ]
[ 61837-46-5 ]

Reference： [1] Patent: WO2010/65865, 2010, A2, . Location in patent: Page/Page column 251

3
[ 67-56-1 ]
[ 28659-88-3 ]
[ 61837-46-5 ]

Reference： [1] Tetrahedron Letters, 1983, vol. 24, # 20, p. 2113 - 2116
[2] Patent: US4251438, 1981, A,
[3] Patent: US2012/142705, 2012, A1, . Location in patent: Page/Page column 14

4
[ 186581-53-3 ]
[ 28659-87-2 ]
[ 61837-46-5 ]

Reference： [1] Patent: WO2004/22526, 2004, A1, . Location in patent: Page 87

5
[ 646-07-1 ]
[ 61837-46-5 ]

Reference： [1] Patent: US2012/142705, 2012, A1,

6
[ 38136-29-7 ]
[ 61837-46-5 ]

Reference： [1] Patent: US2012/142705, 2012, A1,

7
[ 61-90-5 ]
[ 61837-46-5 ]

Reference： [1] Journal of the American Chemical Society, 2014, vol. 136, # 51, p. 17869 - 17881

8
[ 328-39-2 ]
[ 61837-46-5 ]

Reference： [1] Journal of the American Chemical Society, 2014, vol. 136, # 51, p. 17869 - 17881

9
[ 67-56-1 ]
[ 38136-29-7 ]
[ 61837-46-5 ]

Reference： [1] Journal of Organic Chemistry, 1992, vol. 57, # 5, p. 1603 - 1605

10
[ 67-56-1 ]
[ 28659-87-2 ]
[ 61837-46-5 ]

Reference： [1] Journal of the American Chemical Society, 2014, vol. 136, # 51, p. 17869 - 17881

[ 61837-46-5 ] Synthesis Path-Downstream 1~88

1
[ 67-56-1 ]
[ 646-07-1 ]
[ 61837-46-5 ]

Yield	Reaction Conditions	Operation in experiment
66%		Preparation of 2-bromo-4-methyl-pentanoic acid methyl ester: A solution of 4-methyl-pentanoic acid (50 g, 0.43 mol) in carbon tetrachloride (200 mL) at 25 C. was treated with thionyl chloride (125 mL, 1.72 mol). The reaction was then heated to 65 C. and stirred for 30 min. After this time, the reaction was removed from the heat and was then treated with N-bromosuccinimide (100 g, 0.56 mol), carbon tetrachloride (200 mL) and a 48% aqueous hydrogen bromide (40 drops). The reaction was then heated to 85 C. and stirred overnight. After this time, the reaction was cooled to 0 C. and carefully quenched with methanol (150 mL) until no further gas evolution was observed. The mixture was then filtered and washed with hexanes. The dark solution was concentrated in vacuo. The remaining liquid was then partitioned between water (300 mL) and hexanes (3×300 mL). The combined organics were washed with a saturated aqueous sodium bicarbonate solution, dried over anhydrous sodium sulfate, filtered, rinsed and concentrated in vacuo. The obtained residue was distilled in vacuo to afford 2-bromo-4-methyl-pentanoic acid methyl ester as colorless oil (60 g, 66%); 1H NMR (300 MHz, CDCl3): delta 4.28 (t, 1H, J=7.5 Hz), 3.77 (s, 3H), 1.90 (t, 2H, J=7.5 Hz), 1.78-1.71 (m, 1H), 0.93 (dd, 6H, J1=14.1 Hz, J2=6.6 Hz). GC-MS: 209 [M]+, tR=5.50 min.

Reference： [1]European Journal of Organic Chemistry,2011,p. 1300 - 1309
[2]Patent: US2011/21570,2011,A1 .Location in patent: Page/Page column 15
[3]Journal of the Chemical Society. Perkin transactions I,1986,p. 1939 - 1946
[4]Tetrahedron,1992,vol. 48,p. 4773 - 4792
[5]Chemistry - A European Journal,2016,vol. 22,p. 18368 - 18372

2
[ 67-56-1 ]
[ 38136-29-7 ]
[ 61837-46-5 ]

Reference： [1]Journal of Organic Chemistry,1992,vol. 57,p. 1603 - 1605

3
[ 67-56-1 ]
[ 590-28-3 ]
[ 61837-46-5 ]
[ 70304-20-0 ]

Reference： [1]Chemische Berichte,1981,vol. 114,p. 173 - 189

4
[ 594-65-0 ]
[ 61837-46-5 ]
[ 138286-82-5 ]

Reference： [1]Journal of Organic Chemistry,1992,vol. 57,p. 1603 - 1605

5
[ 61837-46-5 ]
[ 108-98-5 ]
[ 86895-67-2 ]

Reference： [1]Tetrahedron Letters,1983,vol. 24,p. 2113 - 2116
[2]Journal of the Chemical Society. Perkin transactions I,1986,p. 1939 - 1946

6
[ 713-68-8 ]
[ 61837-46-5 ]
4-methyl-2-(3-phenoxy-phenoxy)-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505

7
[ 92-69-3 ]
[ 61837-46-5 ]
2-(biphenyl-4-yloxy)-4-methyl-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505
[2]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 6789 - 6806

8
[ 580-51-8 ]
[ 61837-46-5 ]
2-(biphenyl-3-yloxy)-4-methyl-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505
[2]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 6789 - 6806

9
[ 831-82-3 ]
[ 61837-46-5 ]
4-methyl-2-(4-phenoxy-phenoxy)-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505

10
[ 61837-46-5 ]
[ 90-43-7 ]
2-(biphenyl-2-yloxy)-4-methyl-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505
[2]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 6789 - 6806

11
[ 61837-46-5 ]
[ 108-95-2 ]
4-methyl-2-phenoxy-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505
[2]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 6789 - 6806

12
[ 61837-46-5 ]
[ 108-98-5 ]
4-methyl-2-phenylsulfanyl-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 6789 - 6806

13
[ 61837-46-5 ]
N-{2-[(4-methoxyphenyl)amino]ethyl}-4-methyl-2-phenoxypentanamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 6789 - 6806
[2]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505

14
[ 61837-46-5 ]
2-(biphenyl-4-yloxy)-N-{2-[(4-methoxyphenyl)amino]ethyl}-4-methylpentanamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 6789 - 6806
[2]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505

15
[ 61837-46-5 ]
2-(biphenyl-2-yloxy)-N-{2-[(4-methoxyphenyl)amino]ethyl}-4-methylpentanamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 6789 - 6806
[2]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505

16
[ 61837-46-5 ]
2-(biphenyl-3-yloxy)-N-{2-[(4-methoxyphenyl)amino]ethyl}-4-methylpentanamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 6789 - 6806
[2]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505

17
[ 61837-46-5 ]
N-{2-[(4-methoxyphenyl)amino]ethyl}-4-methyl-2-(phenylsulfanyl)pentanamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 6789 - 6806

18
[ 61837-46-5 ]
4-methyl-2-(3-phenoxy-phenoxy)-pentanoic acid [2-(4-methoxy-phenylamino)-ethyl]-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505

19
[ 61837-46-5 ]
4-methyl-2-(4-phenoxy-phenoxy)-pentanoic acid [2-(4-methoxy-phenylamino)-ethyl]-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1502 - 1505

20
[ 61837-46-5 ]
2-(3-bromo-phenoxy)-4-methyl-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

21
[ 61837-46-5 ]
2-(4-bromo-phenoxy)-4-methyl-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

22
[ 61837-46-5 ]
2-(2-bromo-phenoxy)-4-methyl-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

23
[ 61837-46-5 ]
2-(2-bromo-phenylsulfanyl)-4-methyl-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

24
[ 61837-46-5 ]
2-(4-bromo-phenylsulfanyl)-4-methyl-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

25
[ 61837-46-5 ]
2-(3-bromo-phenylsulfanyl)-4-methyl-pentanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

26
[ 61837-46-5 ]
2-(4-bromo-phenoxy)-4-methyl-pentanoic acid cyanomethyl-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

27
[ 61837-46-5 ]
2-(3-bromo-phenylsulfanyl)-4-methyl-pentanoic acid cyanomethyl-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

28
[ 61837-46-5 ]
2-(2-bromo-phenylsulfanyl)-4-methyl-pentanoic acid cyanomethyl-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

29
[ 61837-46-5 ]
2-(4-bromo-phenylsulfanyl)-4-methyl-pentanoic acid cyanomethyl-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

30
[ 61837-46-5 ]
2-(3-bromo-phenoxy)-4-methyl-pentanoic acid cyanomethyl-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

31
[ 61837-46-5 ]
2-(2-bromo-phenoxy)-4-methyl-pentanoic acid cyanomethyl-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4291 - 4295

32
[ 646-07-1 ]
by/at 114 degree melting acid [ No CAS ]
[ 61837-46-5 ]

Reference： [1]Journal of Organic Chemistry,1992,vol. 57,p. 1603 - 1605

33
[ 61837-46-5 ]
[ 2508-63-6 ]

Reference： [1]Journal of Organic Chemistry,1992,vol. 57,p. 1603 - 1605
[2]Chemische Berichte,1981,vol. 114,p. 173 - 189

34
[ 61837-46-5 ]
[ 66716-62-9 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1986,p. 1939 - 1946

35
[ 61837-46-5 ]
[ 66716-62-9 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1986,p. 1939 - 1946
[2]Tetrahedron Letters,1983,vol. 24,p. 2113 - 2116

36
[ 61837-46-5 ]
[ 86895-72-9 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1986,p. 1939 - 1946
[2]Tetrahedron Letters,1983,vol. 24,p. 2113 - 2116

37
[ 186581-53-3 ]
[ 28659-87-2 ]
[ 61837-46-5 ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane; at 20℃; for 0.25h;	EXAMPLE 69; Synthesis of 2-[1-(4-bromophenyl)-2,2,2-trifluoroethoxy]-N-(cyanomethyl)-4-methylpentanamide; Step 1; methyl 2-bromo-4-methylpentanoate; To a solution of 2-bromo-4-methylpentanoic acid (9.86 mmol, 1.31 g) in CH2Cl2 (100mL), was added slowly a solution of diazomethane until no bubbles appears. The mixture was stirred at r.t. for 0.25 h. The volatiles were removed under reduced pressure to leave a yellow liquid. The crude methyl ester was used without further purification.

Reference： [1]Patent: WO2004/22526,2004,A1 .Location in patent: Page 87

38
[ 61837-46-5 ]
[ 78551-30-1 ]

Yield	Reaction Conditions	Operation in experiment
	With ethylenediamine; In ethanol; ethyl acetate; N,N-dimethyl-formamide;	EXAMPLE 4 3-(2-Methylpropyl)piperazinone (VII) A mixture of methyl <strong>[61837-46-5]2-bromo-4-methylpentanoate</strong> (V, Example 3, 14.6 g.) and ethylenediamine (VI, 12.5 g.) in ethanol (250 ml.) is stirred at 20-25 for 20 hours. The ethanol is removed under reduced pressure and the residual oil is partitioned between chloroform and aqueous sodium bicarbonate. The chloroform layer is separated and the chloroform is removed under reduced pressure to give an oil which is refluxed in DMF (20 ml.) for one hour. After removal of the DMF the residue is column chromatographed on silica gel eluding with chloroform-methanol (99/5). Appropriate fractions are pooled and concentrated to give a residue which is dissolved in ethyl acetate (150 ml.) and decolorized with charcoal. Crystallization from ethyl acetate-SSB gives an oily solid which upon crystallization from ethyl acetate-SSB gives the title compound, m.p. 75-77.

Reference： [1]Patent: US4251438,1981,A

39
2-Benzyl-3-oxo-piperazine-1-carboxylic acid benzyl ester [ No CAS ]
[ 61837-46-5 ]
Methyl α-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-1-piperazine acetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In tetrahydrofuran; methanol; ethyl acetate;	EXAMPLE 64 Methyl alpha-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-1-piperazine acetate (XXXI, isomer A is a L,L-; D,D-mixture and isomer B is a L,D-; D,L-mixture) Sodium hydride (1.75 g., 50% in oil) is added to a stirred solution of benzyl 3-oxo-2-(phenylmethyl)-1-piperazinecarboxylate (XXX, Example 63, 10.8 g.) in THF (200 ml.). The mixture is stirred for 15 minutes at which time methyl <strong>[61837-46-5]2-bromo-4-methylpentanoate</strong> (10 g.) is added and stirring is continued for 3 hours. The THF is removed under reduced pressure and the residue is dissolved in ethyl acetate (400 ml.) and methanol (10 ml.). The solution is washed with water (3100 ml.) and saline. Removal of the ethyl acetate gave an oil which is column chromatographed on silica gel. Elution with diethyl ether-SSB (1/1) gives, as the first product eluted from the column "isomer A", a mixture of the L,L- and D,D-isomers, methyl alpha-[(S)-2-methylpropyl]-2-oxo-4-(phenylmethoxycarbonyl)-3-[(S)-phenylmethyl]-1-piperazine acetate and methyl alpha-[(R)-2-methylpropyl]-2-oxo-4-(phenylmethoxycarbonyl)-3-[(R)-phenylmethyl]-1-piperazine acetate, which upon crystallization (2) from ethyl acetate-SSB has a m.p. of 51-54. Continued elution of the column gives "isomer B", a mixture of L,D- and D,L-isomers, methyl alpha-[(S)-2-methylpropyl]-2-oxo-4-(phenylmethoxycarbonyl)-3-[(R)-phenylmethyl]-1-piperazine acetate and methyl alpha-[(R)-2-methylpropyl]-2-oxo-4-(phenylmethoxycarbonyl)-3-[(S)-phenylmethyl]-1-piperazine acetate, pure material is obtained by recrystallization from ethyl acetate and then from methanol to give m.p. 65-70.

Reference： [1]Patent: US4251438,1981,A

40
[ 61837-46-5 ]
[ 70304-20-0 ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 11 14.64 grams of <strong>[61837-46-5]2-bromo-4-methyl valeric acid methyl ester</strong> were brought to reaction with potassium cyanate and methanol in the manner described in Example 1 (using the same amounts of potassium cyanate and methanol as in Example 1), reaction time 1 hour and then worked up. There were obtained 9.39 grams (66%) of 2-methoxycarbonylamino-4-methyl valeric acid methyl ester with a boiling point of 100 C./0.0013 mbar.

Reference： [1]Patent: US4234744,1980,A

41
[ 35320-67-3 ]
[ 61837-46-5 ]
[ 936567-82-7 ]

Yield	Reaction Conditions	Operation in experiment
70%	With potassium carbonate; sodium iodide; In N,N-dimethyl-formamide; at 70℃; for 7h;	[00258] 2-(1-Benzyl-2-methyl-1 H-indol-4-yloxy)-4-methyl-pentanoic acid methyl ester (2):; To a stirred suspension of K2CO3 (0.563 g, 4.22 mmol), NaI (0.031 g, 0.21 mmol) and 1- <n="88"/>y ir theta . g, . mmo n ry > m , a so u ion o (CHs)2CHCH2BrCHCO2Me (0.66 g, 3.2 mmol) in DMF (5 mL) was added dropwise. The reaction mixture was heated at 70 0C for 7 h, cooled to room temperature and water (30 mL) was added. The mixture was extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with water (50 mL), brine (50 mL), dried over Na2SO4 and evaporated. Flash chromatography of the residue over silica gel, using 10% EtOAc in hexanes to 20% EtOAc in hexanes, gave product 2 as a pale yellow solid. Yield: 0.54 g (70%).

Reference： [1]Patent: WO2007/56280,2007,A1 .Location in patent: Page/Page column 86-87

42
[ 61837-46-5 ]
[ 172732-78-4 ]
[ 936567-82-7 ]

Yield	Reaction Conditions	Operation in experiment
70%	With potassium carbonate; sodium iodide; In N,N-dimethyl-formamide; at 70℃; for 7h;Product distribution / selectivity;	[00501] " psi-(1-i&h mmethyl-1H-indol-4-yloxy)-4'methyl-pentanoic acid methyl ester (2):lo a stirred suspension of K2CO3 (0.563 g, 4.22 mmol), NaI (0.031 g, 0.21 mmol) and 1-benzyl-2-methyl-1ry-indol-4-ol (1) (0.500 g, 2.11 mmol) in dry DMF (15 mL), a solution of (CHs)2CHCH2BrCHCO2Me (0.66 g, 3.2 mmol) in DMF (5 mL) was added dropwise. The reaction mixture was heated at 70 0C for 7 h, cooled to room temperature and water (30 mL) was added. The mixture was extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with water (50 mL), brine (50 mL), dried over Na2SO4 and evaporated. Flash chromatography of the residue over silica gel, using 10% EtOAc in hexanes to 20% EtOAc in hexanes, gave product 2 as a pale yellow solid. Yield: 0.54 g (70%).
70%	With potassium carbonate; sodium iodide; In N,N-dimethyl-formamide; at 70℃; for 7h;	To a stirred suspension of K2CO3 (0.563 g, 4.22 mmol), NaI (0.031 g, 0.21 mmol) and 1-benzyl-2-methyl-1H-indol-4-ol (1) (0.500 g, 2.11 mmol) in dry DMF (15 mL), a solution of (CH3)2CHCH2BrCHCO2Me (0.66 g, 3.2 mmol) in DMF (5 mL) was added dropwise. The reaction mixture was heated at 70 C. for 7 h, cooled to room temperature and water (30 mL) was added. The mixture was extracted with EtOAc (3×50 mL). The combined organic extracts were washed with water (50 mL), brine (50 mL), dried over Na2SO4 and evaporated. Flash chromatography of the residue over silica gel, using 10% EtOAc in hexanes to 20% EtOAc in hexanes, gave product 2 as a pale yellow solid. Yield: 0.54 g (70%).
		[00498] 2-(3-(2-amino-2-oxoacetyl)-1 -benzyI-2-methyl-1 H-indol-4-yloxy)-4- methylpentanoic acid (ILY-IV-47); 2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-methyl-1H- indol-4-yloxy)-3,3-dimethylbutanoic acid (ILY-IV-46); 2-(3-(2-amino-2-oxoacetyl)-1- benzyl-2-methyl-1H-indol-4-yloxy)malonic acid (ILY-IV-8); 2-(3-(2-amino-2-oxoacetyl)-1- benzyl-2-methyl-1H-indol-4-yloxy)-2-phosphonoacetic acid (ILY-IV-1); 2-(3-(2-amino-2- oxoacetyl)-1-benzyl-2-methyl-1H-indol-4-yloxy)succinic acid (ILY-IV-19) can be prepared according to the schema shown above and the following description. <n="199"/>anhydrous dimethylformamide (20 mL). To the solution, sodium hydride 60% in mineral oil (1.2 mmole) is added. The mixture is stirred at room temperature for 1 h. To the mixture the corresponding bromo-acetic acid methyl ester (1.2 mmole) is added. The mixture is stirred at room temperature for 18 h. The reaction is diluted with ethyl acetate (300 mL) and washed with H2O (4 x 100 mL) and brine (1 x 100 mL). The organic layer is to be separated, dried with magnesium sulfate and concentrated. The residue is purified by column chromatography to afford 15.

Reference： [1]Patent: WO2007/56279,2007,A2 .Location in patent: Page/Page column 198-199
[2]Patent: US2007/135385,2007,A1 .Location in patent: Page/Page column 99
[3]Patent: WO2007/56279,2007,A2 .Location in patent: Page/Page column 197; 198

43
[ 5555-72-6 ]
[ 61837-46-5 ]
C₁₇H₂₅NO₅ [ No CAS ]

Reference： [1]Synlett,2008,p. 861 - 866

44
[ 80418-12-8 ]
[ 61837-46-5 ]
[ 1374996-91-4 ]

Yield	Reaction Conditions	Operation in experiment
		Step 3; methyl 2-[1-(4-bromophenyl)-2,2,2-trifluoroethoxy]-4-methylpentanoate; Sodium hydride (60% W, 2.16 mmol, 87 mg) was suspended in dry THF and cooled to 0C. A solution of 1-(4-bromophenyl)-2,2,2-trifluoroethanol from example 69 step 2 was added slowly and stirred at 0C over 0.75 h. A solution of methyl <strong>[61837-46-5]2-bromo-4-methylpentanoate</strong> from example 69 step 1 was added and the mixture was allowed to warmed to r.t. and stirred overnight. The reaction was treated with 0.1 N aqueous hydrochloric acid, diluted with diethyl ether and ethyl acetate. The phases are separated and the organic layer was washed with 0.1N aqueous hydrochloric acid then brine and dried over magnesium sulfate. The volatiles were removed under reduced pressure to yield methyl 4-methyl-2-(2,2,2-trifluoro-1-phenylethoxy)pentanoate that was used without further purification.

Reference： [1]Patent: WO2004/22526,2004,A1 .Location in patent: Page 87

45
[ 61837-46-5 ]
(4-bromophenyl)(pyridin-2-yl)methanol [ No CAS ]
methyl 2-[(4-bromophenyl)(pyridin-2-yl)methoxy]-4-methylpentanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Step 2; methyl 2-[(4-bromophenyl)(pyridin-2-yl)methoxy]-4-methylpentanoate;To a solution of (4-bromophenyl)(pyridin-2-yl)methanol from step 1 (720mg,2.73mmol) in DMF (14mL) at 0C, was added sodium hydride portionwise (69mg, 2.87mmol).The mixture was stirred 30 minutes before the methyl <strong>[61837-46-5]2-bromo-4-methylpentanoate</strong> was slowly added (469uL, 2.87mmol). The reaction was allowed to warm to room temperature and was agedfor 3 hours more. The mixture was then poured into brine and extracted 3 times with ethylacetate. The combined organic extracts were dried and concentrated and the crude productobtained was chromatographed on silica gel using 50% ethyl acetate in hexanes to afford the titlecompound.

Reference： [1]Patent: WO2004/22526,2004,A1 .Location in patent: Page 57

46
[ 29334-16-5 ]
[ 61837-46-5 ]
[ 1374997-50-8 ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 73; Synthesis of 2-[(4-bromophenyl)(phenyl)methvnthiol-N-(cyanomethvl)-4-methvlpentanamide; Step 1; methyl 2- [(4-bromophenyl)(phenyl )methyl]thio}-4-methylpentanoate; To a solution of triisopropylsilanethiol (1.75 mL, 8.05 mmoles) and <strong>[29334-16-5](4-bromophenyl)(phenyl)methanol</strong> from example 67 step 2 (3.5 , 8.05 mmoles) in 16 mL of DMF was added sodium hydride as a 60percent emulsion in oil (386 mg, 9.66 mmoles). After the exotherm has passed, 1.65 mL (10 mmole) of methyl 2-bromo-4-methylpentanoate was added followed by10 12 mL of a 1.0 M solution of tetrabutylammonium fluoride in tetrahydrofuran. After stirringovernight, the reaction was diluted with diethyl ether (200mL) and washed twice with 0.1 N HC1, twice with water and once with brine. The organic phase was dried over magnesium sulfate and concentrated under reduced pressure. The oil as purified by flash chromatography (9:1 hexanes to ethyl acetate) to give the title ester.

Reference： [1]Patent: WO2004/22526,2004,A1 .Location in patent: Page 90

47
tert-butyl 4-{4-[hydroxy(phenyl)methyl]benzoyl}piperazine-1-carboxylate [ No CAS ]
[ 61837-46-5 ]
[ 1374987-72-0 ]

Yield	Reaction Conditions	Operation in experiment
		Step 4; tert-butyl 4-{4-[[1-(methoxycarbonyl)-3-methylbutoxy](phenyl)methyl]benzoyl}piperazine-1-carboxylate;To a solution of tert-butyl 4-{4-[hydroxy(phenyl)methyl]benzoyl}piperazine-1-carboxylate from step 3 (1.5g, 3.8mmol) in DMF (20 mL) at 0C was added sodium hydride (0.16g, 4.0mmol) portionwise. The mixture was aged 15 minutes under a nitrogen atmosphere and methyl <strong>[61837-46-5]2-bromo-4-methylpentanoate</strong> (0.65mL, 4.0mmol) was added dropwise. The reaction was allowed to warm to room temperature and was aged for 3 hours. The mixture was then partitioned between ethyl acetate and brine and the organic layer was dried and evaporated. The crude product was chromatographed on silica gel using 40% ethyl acetate in hexanes to afford the title compound.

Reference： [1]Patent: WO2004/22526,2004,A1 .Location in patent: Page 52

49
[ 328-39-2 ]
[ 18107-18-1 ]
[ 61837-46-5 ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 27A methyl 2-bromo-4-methylpentanoate; To concentrated HBr (48%) (20 mL) in water (214 mL), was added KBr (17.6 g, cooled to 0 0C, then sodium nitrite (5.2 g) all at once, then DL-leucine (5.2 g) in a few portions. The reaction was mechanically stirred at 0 0C for 1.5 hours, then extracted with 2 x 200 mL ethyl acetate. The combined organic layers were washed with brine and dried over Na2SO4. After filtration and concentration, the resultant oil was dissolved in CH2Cl2/methanol and treated with 2.0M (TMS)CHN2 in ether (30 mL) at room temperature for 10 minutes. The reaction was concentrated and then purified by flash chromatography using 97.5/2.5 hexane/ethyl acetate.

Reference： [1]Patent: WO2010/65865,2010,A2 .Location in patent: Page/Page column 251

50
[ 61837-46-5 ]
[ 107-15-3 ]
[ 78551-30-1 ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 27B 3 -isobutylpiperazin-2-one; EXAMPLE 27 A (2.2 g) in ethanol (15 mL) was added drop wise over a period of 2.5 hours to a stirred refluxing solution of ethane- 1,2-diamine (13.2 mL) in ethanol (60 mL). Heating was continued for another 2.5 hours, then NaOEt in ethanol was added (21% by wt, 4.0 mL) and heated for another 90 minutes. The reaction was then cooled and concentrated. After trituration with ether, the title compound was used without purification.

Reference： [1]Patent: WO2010/65865,2010,A2 .Location in patent: Page/Page column 251

51
[ 61837-46-5 ]
[ 1378680-06-8 ]

Reference： [1]Journal of the American Chemical Society,2010,vol. 132,p. 11908 - 11909

52
[ 53937-02-3 ]
[ 61837-46-5 ]
[ 1262239-31-5 ]

Yield	Reaction Conditions	Operation in experiment
73%	With potassium carbonate; In N,N-dimethyl-formamide; at 80℃;	Preparation of 2-(4-benzyloxy-2-oxo-2H-pyridin-1-yl)-4-methyl-pentanoic acid methyl ester: A solution of <strong>[53937-02-3]4-benzyloxy-1H-pyridin-2-one</strong> (15 g, 74.6 mmol) in N,N,-dimethylformamide (200 mL) was treated with 2-bromo-4-methyl-pentanoic acid methyl ester (29.2 g, 112 mmol, 80% purity) and potassium carbonate (15.5 g, 112 mmol). The mixture was stirred at 80 C. overnight. At this time, the reaction was allowed to cool to 25 C. and was then concentrated to dryness in vacuo. The residue was washed with ethyl acetate (300 mL) and the remaining solid was removed by filtration. The filtrate was concentrated in vacuo. Flash column chromatography (ethyl acetate:petroleum ether:1:2) afforded 2-(4-benzyloxy-2-oxo-2H-pyridin-1-yl)-4-methyl-pentanoic acid methyl ester (18 g, 73%); 1H NMR (300 MHz, CDCl3): delta 7.41-7.36 (m, 5H), 7.21 (d, 1H, J=7.8 Hz), 6.06-6.00 (m, 2H), 5.7 (dd, 1H, J1=10.5 Hz, J2=5.4 Hz), 4.99 (s, 2H), 3.71 (s, 3H), 1.96-1.86 (m, 2H), 1.49-1.42 (m, 1H), 0.96 (d, 3H, J=6.6 Hz), 0.93 (d, 3H, J=6.9 Hz), LC-MS: 330 [M+1]+, tR=2.71 min.

Reference： [1]Patent: US2011/21570,2011,A1 .Location in patent: Page/Page column 15

53
[ 1519-39-7 ]
[ 61837-46-5 ]
[ 1279699-94-3 ]

Reference： [1]European Journal of Organic Chemistry,2011,p. 1300 - 1309

54
[ 61837-46-5 ]
[ 1279699-97-6 ]

Reference： [1]European Journal of Organic Chemistry,2011,p. 1300 - 1309

55
[ 61837-46-5 ]
[ 1279700-01-4 ]

Reference： [1]European Journal of Organic Chemistry,2011,p. 1300 - 1309

56
[ 61837-46-5 ]
[ 1326230-96-9 ]
[ 1279700-01-4 ]

Reference： [1]European Journal of Organic Chemistry,2011,p. 1300 - 1309

57
[ 61837-46-5 ]
C₂₈H₃₅NOS [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2011,p. 1300 - 1309
[2]European Journal of Organic Chemistry,2011,p. 1300 - 1309

58
[ 61837-46-5 ]
[ 171815-93-3 ]

Reference： [1]European Journal of Organic Chemistry,2011,p. 1300 - 1309
[2]European Journal of Organic Chemistry,2011,p. 1300 - 1309

59
[ 87-48-9 ]
[ 61837-46-5 ]
[ 1380287-16-0 ]

Yield	Reaction Conditions	Operation in experiment
90%		Example 68 2-(5-Bromo-2,3-dioxo-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid pyrazin-2-ylamide A stirred suspension of sodium hydride (60% dispersion in oil, 212 mg) in N,N-dimethylformamide (10 mL) at 0 C. was treated with a solution of 5-bromo-1H-indole-2,3-dione (1.0 g) in N,N-dimethylformamide. The reaction mixture was stirred for 30 min at 0 C. and then 2-bromo-4-methyl-pentanoic acid methyl ester (prepared as in Example 9, 1.11 g) was added and it was stirred for 1 h at 0 C. It was then slowly allowed to warm to room temperature and stirred for another 3 h at room temperature. After this time, the reaction mixture was diluted with water and extracted with chloroform. The organic layers were combined and dried over sodium sulfate, filtered and the filterate concentrated in vacuo. The crude material was purified by column chromatography (silica gel, 5% ethyl acetate/hexanes) to afford 2-(5-bromo-2,3-dioxo-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid methyl ester (1.4 g, 90%).

Reference： [1]Patent: US2012/142705,2012,A1 .Location in patent: Page/Page column 34

60
[ 91-56-5 ]
[ 61837-46-5 ]
[ 1380286-82-7 ]

Yield	Reaction Conditions	Operation in experiment
72%		A stirred suspension of sodium hydride (39 mg) in N,N-dimethylformamide (5 mL) at 0 C. was treated with a solution of 1H-indole-2,3-dione (0.20 g) in N,N-dimethylformamide. The reaction mixture was stirred for 30 min at 0 C. and then 2-bromo-4-methyl-pentanoic acid methyl ester (341 mg) was added and it was stirred for 1 h at 0 C. It was then slowly allowed to warm to room temperature and stirred for another 3 h at room temperature. After this time, the reaction mixture was diluted with water and extracted with methylene chloride. The organic layers were combined and dried over sodium sulfate, filtered and the filterate concentrated in vacuo. The crude material was purified by column chromatography (silica gel) to afford 2-(2,3-dioxo-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid methyl ester (250 mg, 72%).

Reference： [1]Patent: US2012/142705,2012,A1 .Location in patent: Page/Page column 14

61
[ 61837-46-5 ]
[ 169037-23-4 ]
[ 1380286-97-4 ]

Yield	Reaction Conditions	Operation in experiment
64%		Example 37 2-(2,3-Dioxo-5-trifluoromethoxy-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid pyrazin-2-ylamide A stirred suspension of sodium hydride (60% dispersion in oil, 208 mg) in N,N-dimethylformamide (25 mL) at 0 C. was treated with a solution of 5-trifluoromethoxy-1H-indole-2,3-dione (1.0 g) in N,N-dimethylformamide. The reaction mixture was stirred for 30 min at 0 C. and then 2-bromo-4-methyl-pentanoic acid methyl ester (prepared as in Example 9, 1.1 g) was added and it was stirred for 1 h at 0 C. It was then slowly allowed to warm to room temperature and stirred for another 3 h at room temperature. After this time, the reaction mixture was diluted with water and extracted with methylene chloride. The organic layers were combined and dried over sodium sulfate, filtered and the filterate concentrated in vacuo. The crude material was purified by column chromatography (silica gel) to afford 2-(2,3-dioxo-5-trifluoromethoxy-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid methyl ester (1.0 g, 64%).

Reference： [1]Patent: US2012/142705,2012,A1 .Location in patent: Page/Page column 23-24

62
[ 646-07-1 ]
[ 61837-46-5 ]

Reference： [1]Patent: US2012/142705,2012,A1

63
[ 608-05-9 ]
[ 61837-46-5 ]
[ 1380287-22-8 ]

Yield	Reaction Conditions	Operation in experiment
56%		Example 84 4-Methyl-2-(5-methyl-2,3-dioxo-2,3-dihydro-indol-1-yl)-pentanoic acid pyrazin-2-ylamide A stirred suspension of sodium hydride (60% dispersion in oil, 297 mg) in N,N-dimethylformamide (15 mL) at 0 C. was treated with a solution of 5-methyl-1H-indole-2,3-dione (1.0 g) in N,N-dimethylformamide. The reaction mixture was stirred for 30 min at 0 C. and then 2-bromo-4-methyl-pentanoic acid methyl ester (prepared as in Example 9, 1.56 g) was added and it was stirred for 1 h at 0 C. It was then slowly allowed to warm to room temperature and stirred for another 3 h at room temperature. After this time, the reaction mixture was diluted with water and extracted with chloroform. The organic layers were combined and dried over sodium sulfate, filtered and the filterate concentrated in vacuo. The crude material was purified by column chromatography (silica gel, 5% ethyl acetate/hexanes) to afford 4-methyl-2-(5-methyl-2,3-dioxo-2,3-dihydro-indol-1-yl)-pentanoic acid methyl ester (1.0 g, 56%).

Reference： [1]Patent: US2012/142705,2012,A1 .Location in patent: Page/Page column 40

64
[ 6341-92-0 ]
[ 61837-46-5 ]
[ 1380287-32-0 ]

Yield	Reaction Conditions	Operation in experiment
76%		Example 109 2-(6-Chloro-2,3-dioxo-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid thiazol-2-ylamide A mixture of sodium hydride (60% in oil, 264 mg) in N,N-dimethylformamide at 0 C. was treated with a solution of 6-chloro-1H-indole-2,3-dione (1.0 g) in N,N-dimethyl formamide (total volume is 25 mL). The reaction mixture was then stirred for 30 min at 0 C. After this time, the reaction mixture was treated with 2-bromo-4-methyl-pentanoic acid methyl ester (prepared as in Example 9, 1.38 g) and stirred for another 1 h at 0 C. The reaction mixture was then allowed to warm to room temperature and stirred for 3 h. After this time, the reaction was diluted with water and extracted with methylene chloride. The organic layers were combined and then dried over sodium sulfate, filtered to remove the drying agent and the filterate concentrated in vacuo. The residue obtained was then purified by silica gel column chromatography to afford 2-(6-chloro-2,3-dioxo-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid methyl ester (1.3 g, 76%).

Reference： [1]Patent: US2012/142705,2012,A1 .Location in patent: Page/Page column 48-49

65
[ 17630-76-1 ]
[ 61837-46-5 ]
[ 1380287-29-5 ]

Yield	Reaction Conditions	Operation in experiment
59%		Example 101 2-(5-Chloro-2,3-dioxo-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid thiazol-2-ylamide A stirred suspension of sodium hydride (159 mg) in N,N-dimethylformamide (15 mL) at 0 C. was treated with a solution of 5-chloro-1H-indole-2,3-dione (1.0 g) in N,N-dimethylformamide. The reaction mixture was stirred for 30 min at 0 C. and then 2-bromo-4-methyl-pentanoic acid methyl ester (prepared as in Example 9, 1.38 g) was added and it was stirred for 1 h at 0 C. It was then slowly allowed to warm to room temperature and stirred for another 3 h at room temperature. After this time, the reaction mixture was diluted with water and extracted with methylene chloride. The organic layers were combined and dried over sodium sulfate, filtered and the filterate concentrated in vacuo. The crude material was purified by column chromatography (silica gel) to afford 2-(5-chloro-2,3-dioxo-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid methyl ester (1.0 g, 59%).

Reference： [1]Patent: US2012/142705,2012,A1 .Location in patent: Page/Page column 46

66
[ 39755-95-8 ]
[ 61837-46-5 ]
[ 1380287-07-9 ]

Yield	Reaction Conditions	Operation in experiment
87%		Example 53 2-(5-Methoxy-2,3-dioxo-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid pyrazin-2-ylamide A stirred suspension of sodium hydride (60% dispersion in oil, 271 mg) in N,N-dimethylformamide (25 mL) at 0 C. was treated with a solution of 5-methoxy-1H-indole-2,3-dione (1.0 g) in N,N-dimethylformamide. The reaction mixture was stirred for 30 min at 0 C. and then 2-bromo-4-methyl-pentanoic acid methyl ester (prepared as in Example 9, 1.4 g) was added and it was stirred for 1 h at 0 C. It was then slowly allowed to warm to room temperature and stirred for another 3 h at room temperature. After this time, the reaction mixture was diluted with water and extracted with methylene chloride. The organic layers were combined and dried over sodium sulfate, filtered and the filterate concentrated in vacuo. The crude material was purified by column chromatography (silica gel) to afford 2-(5-methoxy-2,3-dioxo-2,3-dihydro-indol-1-yl)-4-methyl-pentanoic acid methyl ester (1.5 g, 87%).

Reference： [1]Patent: US2012/142705,2012,A1 .Location in patent: Page/Page column 29

67
[ 61837-46-5 ]
[ 1380285-49-3 ]

Reference： [1]Patent: US2012/142705,2012,A1

68
[ 61837-46-5 ]
[ 1380285-50-6 ]

Reference： [1]Patent: US2012/142705,2012,A1

69
[ 61837-46-5 ]
[ 1380285-77-7 ]

Reference： [1]Patent: US2012/142705,2012,A1

70
[ 61837-46-5 ]
[ 1380285-78-8 ]

Reference： [1]Patent: US2012/142705,2012,A1

71
[ 61837-46-5 ]
[ 1380285-79-9 ]

Reference： [1]Patent: US2012/142705,2012,A1

72
[ 61837-46-5 ]
[ 1380285-80-2 ]

Reference： [1]Patent: US2012/142705,2012,A1

73
[ 61837-46-5 ]
[ 1380285-93-7 ]

Reference： [1]Patent: US2012/142705,2012,A1

74
[ 61837-46-5 ]
[ 1380285-94-8 ]

Reference： [1]Patent: US2012/142705,2012,A1

75
[ 61837-46-5 ]
[ 1380285-95-9 ]

Reference： [1]Patent: US2012/142705,2012,A1

76
[ 61837-46-5 ]
[ 1380286-08-7 ]

Reference： [1]Patent: US2012/142705,2012,A1

77
[ 61837-46-5 ]
[ 1380286-09-8 ]

Reference： [1]Patent: US2012/142705,2012,A1

78
[ 61837-46-5 ]
[ 1380286-10-1 ]

Reference： [1]Patent: US2012/142705,2012,A1

79
[ 61837-46-5 ]
[ 1380286-11-2 ]

Reference： [1]Patent: US2012/142705,2012,A1

80
[ 61837-46-5 ]
[ 1380286-24-7 ]

Reference： [1]Patent: US2012/142705,2012,A1

81
[ 61837-46-5 ]
[ 1380286-25-8 ]

Reference： [1]Patent: US2012/142705,2012,A1

82
[ 61837-46-5 ]
[ 1380286-26-9 ]

Reference： [1]Patent: US2012/142705,2012,A1

83
[ 61837-46-5 ]
[ 1380286-27-0 ]

Reference： [1]Patent: US2012/142705,2012,A1

84
[ 61837-46-5 ]
[ 1380286-41-8 ]

Reference： [1]Patent: US2012/142705,2012,A1

85
[ 61837-46-5 ]
[ 1380286-42-9 ]

Reference： [1]Patent: US2012/142705,2012,A1

86
[ 61837-46-5 ]
[ 1380286-43-0 ]

Reference： [1]Patent: US2012/142705,2012,A1

87
[ 67-56-1 ]
[ 28659-87-2 ]
[ 61837-46-5 ]

Reference： [1]Journal of the American Chemical Society,2014,vol. 136,p. 17869 - 17881

88
[ 29334-16-5 ]
[ 61837-46-5 ]
2-[(4-bromophenyl)(phenyl )methyl]thio}-4-methylpentanoic acid [ No CAS ]

Reference： [1]Patent: WO2004/22526,2004,A1

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 61837-46-5 ]

Aliphatic Chain Hydrocarbons

[ 50995-48-7 ]

Methyl 2,5-dibromopentanoate

Similarity: 0.94

[ 868-72-4 ]

Dimethyl 2,5-dibromohexanedioate

Similarity: 0.94

[ 760-94-1 ]

Dimethyl 2-bromopentanedioate

Similarity: 0.94

[ 5445-29-4 ]

Ethyl 2-bromooctanoate

Similarity: 0.92

[ 869-10-3 ]

Diethyl 2,5-dibromohexanedioate

Similarity: 0.92

Bromides

[ 50995-48-7 ]

Methyl 2,5-dibromopentanoate

Similarity: 0.94

[ 868-72-4 ]

Dimethyl 2,5-dibromohexanedioate

Similarity: 0.94

[ 760-94-1 ]

Dimethyl 2-bromopentanedioate

Similarity: 0.94

[ 1200828-74-5 ]

Ethyl 2-bromo-2-cyclopropylacetate

Similarity: 0.92

[ 869-10-3 ]

Diethyl 2,5-dibromohexanedioate

Similarity: 0.92

Esters

[ 50995-48-7 ]

Methyl 2,5-dibromopentanoate

Similarity: 0.94

[ 868-72-4 ]

Dimethyl 2,5-dibromohexanedioate

Similarity: 0.94

[ 760-94-1 ]

Dimethyl 2-bromopentanedioate

Similarity: 0.94

[ 1200828-74-5 ]

Ethyl 2-bromo-2-cyclopropylacetate

Similarity: 0.92

[ 869-10-3 ]

Diethyl 2,5-dibromohexanedioate

Similarity: 0.92

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 61837-46-5 ] {[proInfo.proName]}

Quality Control of [ 61837-46-5 ]

Related Doc. of [ 61837-46-5 ]

Product Details of [ 61837-46-5 ]

Safety of [ 61837-46-5 ]

Application In Synthesis of [ 61837-46-5 ]

[ 61837-46-5 ] Synthesis Path-Upstream 1~10

[ 61837-46-5 ] Synthesis Path-Downstream 1~88

Related Functional Groups of [ 61837-46-5 ]

Aliphatic Chain Hydrocarbons

Bromides

Esters

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 61837-46-5 ]